AAHP Reader Favorites for 2022

As we enter 2023, it’s time to look back at our top articles of 2022. These five pieces were the most-read content over the past year. Thank you for your continued support of AAHP!

1. Grocer H-E-B Cultivates the Natural Product Shopper; AAHP Gives Top Honor

The most viewed article highlighted H-E-B being honored with the AAHP Integrative Medicine Retailer Award at our Annual Industry Reception. A one-stop health-and-wellness retailer in Texas, H-E-B continues to help consumers navigate their health journeys while promoting local products, donating to community causes, and investing in environmental efforts.

2. Pharmacy Spotlight: Don Summerfield of Medly Pharmacy

AAHP’s one-on-one interview for our Pharmacy Spotlight series with Don Summerfield, vice president of integrative medicine at Medly Pharmacy, was the second most viewed article in 2022. Don shared expertise on an array of informative topics, including the history of Medly Pharmacy, to what he believes the future of homeopathy looks like.

3. The AAHP Industry Reception: An Evening of Extraordinary Networking

Rounding out the top three articles of 2022 was a recap of the Annual AAHP Industry Reception from President Mark Land. In September, we celebrated the industry with our fourth annual Industry Reception and presented the Integrative Medicine Retailer Award to H-E-B. With 50 attendees, this intimate event served as a great way to connect and support retailers who champion the industry.

4. FDA Warning Letters for Skin Tag and Mole Removal OTCs

In our fourth most-read article of 2022, AAHP Legal Counsel Alvin Lorman discussed an important reminder from the Food and Drug Administration (FDA). In August, FDA issued Warning Letters to several companies for selling products for skin tag removal on their websites. FDA reminded these over-the-counter drug manufacturers that mole and skin tag removal are prescription-only indications.

5. AAHP Submits Comments and Briefs Industry on New FDA Requirements

Our fifth most-read article of last year summarized AAHP’s comments about the new FDA requirements. In November 2021, the FDA announced guidance regarding annual reporting of quantities of drugs manufactured or compounded. AAHP filed comments focused heavily on the large variety of homeopathic drug products and the relatively small quantities produced in comparison with the goals of collecting the information laid out in Section 31129(e) of the CARES Act. AAHP also requested a revision of the guidance to only require the submission of relevant and meaningful information.